• 学术搜索
  • 科研智能体
    • Research Labs
    • AI 阅读
    • AI 文库
    • 深度研究
    • 学者亮点
  • 学术资源
    • AI2000
    • 期刊/会议
    • 学者库
    • 学术API
      MCP&Skill
    • 溯源树
    • 数据集
  • 知识沉淀
    • 学术空间
订阅小程序
旧版功能
aminer vip
开通会员低至0.73元/天
一次搞定AI科研
立即登录
  • English
  • 联系方式
    BMJ Open Respiratory Research

    BMJ Open Respiratory Research

    JournalISSN 2052-4439eISSN 2052-4439中科院 医学 3区

    年发文量

    研究主题

    论文(1682)

    排序
    1Clinical Impact of Updated Cardiopulmonary Exercise Testing Guidelines in Lung Cancer Surgery
    Kristofer Hedman,Karolina Kristenson

    Objectives Cardiopulmonary exercise testing (CPET) has been central to preoperative risk assessment before lung cancer surgery since the European Respiratory Society (ERS)/European Society of Thoracic Surgeons (ESTS) guideline was introduced in 2009. The guideline was recently updated, including incorporation of ventilatory efficiency (ventilation (VE)/carbon dioxide elimination (VCO₂) slope) and revised thresholds for risk stratification. We aimed to determine how application of the updated ERS/ESTS CPET algorithm from 2025 reclassifies physiological risk compared with the 2009 version and to assess the clinical consequences in terms of major postoperative complications across risk categories.Methods We retrospectively analysed 506 patients who underwent CPET during evaluation for suspected or confirmed lung cancer (2008–2020). Risk categorisation was applied according to both 2009 and 2025 ERS/ESTS CPET algorithms. For patients proceeding to lobectomy (n=138), we compared discrimination and predictive values for major pulmonary complications or death within 30 days.Results Risk group distribution shifted markedly: low/intermediate/high risk changed from 20%/78%/2% (2009) to 42%/33%/25% (2025). Among those classified as high risk by the 2025 algorithm (n=127), 91% were newly identified, primarily due to VE/VCO₂-slope >40. In the lobectomy subset, area under the curve was 0.61 for the 2025 algorithm versus 0.57 for 2009 (p=0.998).Conclusion The 2025 ERS/ESTS guideline substantially redistributes patients across risk categories, largely driven by incorporation of VE/VCO₂ slope. Overall discrimination was modest and did not differ from the 2009 algorithm. Although patients classified as high risk according to the 2025 algorithm had the highest observed event rate, selection for surgery under the previous guideline limits conclusions regarding the prognostic validity of the expanded high-risk category.

    2026
    引用
    AI阅读
    加入学术空间
    2Reducing Inhaler Misuse in COPD Outpatients: Protocol for a Randomised Trial
    Julien Vaucher,Philipp Suter,Gaël Grandmaison, Mohamed Faouzi,Brice Touilloux, Samy Bensaid

    Introduction Incorrect inhaler use is common in chronic obstructive pulmonary disease (COPD), with 50%–70% of patients making critical technique errors and up to 40% generating inadequate peak inspiratory flow (PIF). Both mechanisms impair drug delivery and are associated with worse clinical outcomes. Evidence from randomised trials evaluating structured outpatient interventions remains limited. This study evaluates whether a physiotherapist-led inhaler optimisation programme reduces inhaler misuse at 12 months compared with usual care.Methods and analysis Assessment and Improvement of Inhaler Misuse in Outpatients with COPD is a pragmatic, single-centre, parallel-group, superiority randomised controlled trial conducted in outpatient respiratory clinics in Switzerland. Adults with spirometry-confirmed COPD using at least one maintenance inhaler are randomised 1:1 to a structured physiotherapist-led programme or usual care. The intervention includes visits at 3, 6 and 9 months with inhaler technique assessment, PIF measurement using a standardised protocol and teach-to-goal education, with device adaptation if needed.The primary outcome is the proportion of inhalers misused at 12 months, defined as ≥1 critical technique error or inadequate PIF. Secondary outcomes include symptoms, health status, adherence, inhaler satisfaction, lung function and COPD exacerbations. The primary analysis will use mixed-effects logistic regression with a random intercept for patient to account for clustering of inhalers within individuals.Ethics and dissemination The study was approved by the Cantonal Ethics Committee of Vaud, Switzerland (BASEC 2025-02437). Results will be disseminated through peer-reviewed publications. De-identified data will be available on reasonable request.Trial registration number NCT07264140.

    2026
    引用
    AI阅读
    加入学术空间
    3Cost-effectiveness of a Simplified Single-Inhaler Treatment Strategy for Obstructive Lung Disease in Vietnam
    Stephen Jan,Lei Si,Guy B Marks,Helen K Reddel,Thomas Gadsden,Thu-Anh Nguyen,Gregory J Fox,Van Giap Vu, Qingbin Li,Yen Pham Ngoc,Quy Chau Ngo

    Introduction Chronic airways diseases impose substantial clinical and economic burdens in Vietnam. Established treatment algorithms require differentiation between asthma and chronic obstructive pulmonary disease (COPD), which can limit access to appropriate treatment at the primary care level. The Vietnam COPD, Asthma and Prevention of Smoking (VCAPS4) trial evaluated a simplified anti-inflammatory reliever algorithm using a single inhaler (budesonide-formoterol 160/4.5 μg) for adults presenting with undifferentiated chronic airways disease.Methods We conducted a 12-month cost-effectiveness analysis alongside the VCAPS4 trial from the Vietnamese health system perspective. A total of 3095 participants were included (control: 1421; intervention: 1674). Outcomes were exacerbations avoided and quality-adjusted life-years (QALYs), using COPD-based cost and utility inputs to reflect disease severity. Deterministic, probabilistic and scenario analyses were performed.Results Compared with usual care, the intervention reduced exacerbations and generated an additional 0.019 QALYs (95% CI 0.012 to 0.025) at a lower mean cost (−INT$44 per participant). The intervention was dominant, saving INT$210 per exacerbation avoided and INT$2342 per QALY gained. Savings were greatest among participants with reversible or mixed (fixed and reversible) airflow limitation. Among participants without airflow limitation, the intervention cost an additional INT$238 per exacerbation avoided. Findings were robust across sensitivity and scenario analyses.Conclusions Compared with usual care, a simplified, single-inhaler strategy was cost-effective for managing undifferentiated chronic airways disease in Vietnam, with lower mean costs, increased QALYs and a 100% probability of being cost-effective at Vietnam’s willingness-to-pay threshold.

    2026
    引用
    AI阅读
    加入学术空间
    4Bisoprolol Prophylaxis Was Associated with Fewer Early Supraventricular Arrhythmias after Lung Transplantation: a Time-Dependent Cohort Analysis
    David Iturbe-Fernández, Pedro J. Argos-Vélez,Víctor M. Mora-Cuesta,Sandra Tello-Mena,Sheila Izquierdo-Cuervo, Borja Suberviola-Cañas,Laura Sánchez-Moreno,Pilar Alonso-Lecue, Eduardo Miñambres, María de los Ángeles Ballesteros-Sanz

    Background Supraventricular arrhythmias (SVA) are common after lung transplantation (LT) but evidence supporting pharmacological prophylaxis is limited.Methods We retrospectively studied 470 LT recipients transplanted from 2015 to 2025 after excluding early deaths and pre-existing atrial fibrillation. Qualifying prophylaxis was defined as bisoprolol initiated within 30 postoperative days and before the first SVA. The primary outcome was first in-hospital atrial fibrillation, atrial flutter or supraventricular tachycardia. To account for the actual day of treatment initiation, bisoprolol was analysed as a time-dependent exposure in multivariable Cox regression, allowing baseline SVA risk to differ by transplant year.Results Overall, 183 recipients met the prophylaxis definition and 87 (18.5%) developed SVA. Bisoprolol was associated with a lower overall hazard of SVA (adjusted HR 0.14, 95% CI 0.05 to 0.41; p<0.001). The association was strongest early after LT and weakened over time (p=0.014), with adjusted HRs of 0.03 (95% CI 0.003 to 0.27) on day 7 and 0.19 (95% CI 0.05 to 0.70) on day 14. Results were consistent across sensitivity analyses. Potential adverse events occurred in 38 of 201 bisoprolol-treated recipients (18.9%), but serious events were uncommon (2 of 201; 1.0%).Conclusion Bisoprolol prophylaxis was associated with fewer early in-hospital SVA after LT. Prospective studies are required to confirm its efficacy and safety in haemodynamically stable recipients.

    2026
    引用
    AI阅读
    加入学术空间
    5High Prevalence of Pulmonary Abnormalities in Adults with Oesophageal Atresia: Findings from a Structured Follow-Up Programme
    René M H Wijnen,Hanneke IJsselstijn,John Vlot,Pierluigi Ciet, Stephanie A E Wintels, Julian F A van de Ven, Lidewij S Visser, Arnold J F Duinisveld,Lieke S Kamphuis

    Introduction Respiratory comorbidities are common in adults with oesophageal atresia (OA), yet this group remains under-recognised in respiratory medicine. Despite guidelines advocating for structured pulmonary follow-up—including pulmonary function tests (PFTs) and chest CT imaging—implementation remains inconsistent. We aimed to assess respiratory outcomes in relation to anatomical abnormalities in a cohort of adult patients with OA to evaluate the need for standardised pulmonary surveillance.Methods This retrospective cross-sectional study included adults with OA enrolled in the Erasmus Medical Center transition and follow-up programme between 2019 and 2022. All patients underwent pulmonology consultation, PFTs and chest CT imaging.Results Of 182 patients (mean age 33±11 years, 9% OA type A, 85% OA type C), 128 patients (71%) showed abnormalities on CT imaging. Findings included bronchiectasis (12%), tracheomalacia (39%) and tracheal diverticulum (79%). 83 patients (46%) reported respiratory symptoms, most frequently dyspnoea (31%), cough (27%) and sputum production (11%). Symptom burden was associated with CT abnormalities (p=0.022). Interestingly, 62% of asymptomatic patients showed structural changes on chest CT. Bronchiectasis was more prevalent in patients reporting cough and/or sputum than in asymptomatic individuals (21% vs 9%, p=0.019). Mean prebronchodilator PFT z-scores (±SD) were: total lung capacity −1.34 (±1.32), forced expiratory volume in 1 s (FEV1) −1.75 (±1.33) and FEV1/forced vital capacity −0.67 (±1.16).Discussion The high prevalence of respiratory abnormalities both in symptomatic and asymptomatic patients emphasises that adults with OA need routine long-term pulmonary follow-up. Standardised assessments—including PFTs and CT imaging—may be valuable in lifelong OA care to enable early detection and management of respiratory complications.

    2026
    引用
    AI阅读
    加入学术空间
    立即登录,查看全部 1682 篇论文

    高被引作者

    作者引用发文
    Michael Loebinger13024
    Charles S Haworth12983
    Andres Floto12982
    Robert Wilson12982
    Vincent Cottin8878
    Toby Maher88311
    David J. Lederer8413
    Andrew Fisher7974
    Thomas Gorsuch7792
    Michael Kreuter7779

    高产作者

    作者引用发文
    Nick Hopkinson57121
    Christer Janson14919
    Najib M Rahman30818
    Jennifer Quint36916
    Matthew Evison12715
    Magnus P Ekstrom15615
    Elphick Heather E014
    Keir Philip36613
    Nick Maskell15212
    Adam Lewis17312

    相关期刊

    Respirology
    Expert review of respiratory medicine
    Annals of the American Thoracic Society
    ERJ open research
    European Respiratory Review
    Respiratory Medicine
    Current Opinion in Pulmonary Medicine
    Pulmonology
    Thorax
    Archivos De Bronconeumologia